Compare CABA & AIIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CABA | AIIO |
|---|---|---|
| Founded | 2017 | N/A |
| Country | United States | United Arab Emirates |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Auto Manufacturing |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 227.2M | 196.4M |
| IPO Year | 2019 | N/A |
| Metric | CABA | AIIO |
|---|---|---|
| Price | $2.39 | $0.29 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 8 | 0 |
| Target Price | ★ $13.50 | N/A |
| AVG Volume (30 Days) | 2.2M | ★ 9.1M |
| Earning Date | 11-10-2025 | 02-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $5,742,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.99 | $0.25 |
| 52 Week High | $3.67 | $3.48 |
| Indicator | CABA | AIIO |
|---|---|---|
| Relative Strength Index (RSI) | 48.61 | 28.07 |
| Support Level | $2.32 | $0.46 |
| Resistance Level | $2.48 | $0.51 |
| Average True Range (ATR) | 0.14 | 0.08 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 17.50 | 11.08 |
Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies and exploring their potential to provide a deep and durable, perhaps curative, treatment for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells, that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies: CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) that have the potential to be applied across a broad range of autoimmune diseases.
Robo.ai Inc is a pioneering smart electric vehicle company which aims to integrate avant-garde design, life-style personalization, IoT connectivity, and autonomous driving technology into a passenger-centric green premium mobility solution to the world. Geographically, the company operates in The United States, The United Arab Emirates, Mainland China.